CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-20 | Jones Jeffrey Alan Chief Medical Officer | Sale | −387 | $12.94 | $5K | 58,437 |
| 2023-06-20 | Michaelson Jennifer Chief Development Officer | Sale | −238 | $12.94 | $3K | 90,033 |
| 2023-06-20 | Trigilio Jeffrey Chief Financial Officer | Sale | −399 | $12.94 | $5K | 85,823 |
| 2023-06-20 | SUMER JACQUELYN L Chief Legal Officer | Sale | −291 | $12.94 | $4K | 45,823 |
| 2023-06-12 | Trigilio Jeffrey Chief Financial Officer | Sale | −319 | $13.11 | $4K | 86,222 |
| 2023-06-12 | Michaelson Jennifer Chief Development Officer | Sale | −176 | $13.11 | $2K | 90,271 |
| 2023-06-08 | Ebeling Thomas Director | Grant or award · Stock Option (Right to Buy) | +18,450 | 18,450 | ||
| 2023-06-08 | Rosenberg Anthony Director | Grant or award · Stock Option (Right to Buy) | +18,450 | 18,450 | ||
| 2023-06-08 | Webster Stephen W Director | Grant or award · Stock Option (Right to Buy) | +18,450 | 18,450 | ||
| 2023-06-08 | Martin Anne-Marie Director | Grant or award · Stock Option (Right to Buy) | +18,450 | 18,450 | ||
| 2023-06-07 | Michaelson Jennifer Chief Development Officer | Option exercise 10b5-1 | +100 | $4.30 | $430 | 90,547 |
| 2023-06-07 | Michaelson Jennifer Chief Development Officer | Sale 10b5-1 | −100 | $12.40 | $1K | 90,447 |
| 2023-06-07 | Michaelson Jennifer Chief Development Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100 | 188,593 | ||
| 2023-06-06 | Michaelson Jennifer Chief Development Officer | Option exercise 10b5-1 | +11,900 | $4.30 | $51K | 102,347 |
| 2023-06-06 | Michaelson Jennifer Chief Development Officer | Sale 10b5-1 | −11,900 | $12.31 | $146K | 90,447 |
| 2023-06-06 | Michaelson Jennifer Chief Development Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,900 | 188,693 | ||
| 2023-05-23 | AHMED NADIM President and CEO | Sale | −707 | $9.15 | $6K | 116,581 |
| 2023-05-18 | Michaelson Jennifer Chief Development Officer | Sale | −239 | $8.76 | $2K | 90,447 |
| 2023-05-18 | Jones Jeffrey Alan Chief Medical Officer | Sale | −394 | $8.76 | $3K | 58,824 |
| 2023-05-18 | SUMER JACQUELYN L Chief Legal Officer | Sale | −291 | $8.76 | $3K | 46,114 |
Page 9 of 23 · 446 trades